BACE1 vs BACE2 — Antibody Selection

BACE1 (β-secretase 1, BACE1) and BACE2 (β-secretase 2, BACE2) are membrane-anchored aspartic proteinases that share the same overall architecture: an N-terminal propeptide, two catalytic aspartate motifs in a bilobed active site, a transmembrane helix, and a short cytoplasmic tail. They are close paralogues — the human proteins are approximately 64% identical over the catalytic domain and 45% identical overall — and both cleave amyloid precursor protein (APP) in vitro, which is where most of the confusion begins.

They are not, however, biologically interchangeable. BACE1 is the physiologically relevant β-secretase in neurons and the rate-limiting enzyme in amyloid-β production. BACE2 is expressed most highly in pancreatic β-cells and pigment cells, cleaves APP at a different site (the θ site, within Aβ), degrades Aβ rather than producing it, and processes distinct substrates including PMEL and TMEM27. If your antibody detects both indiscriminately, your Western blot cannot answer any biologically meaningful question about either.

When you need to discriminate BACE1 from BACE2

Some experimental questions do not require paralogue discrimination — if you are running a knockdown validation of a BACE1-specific siRNA in HEK cells that do not express BACE2, a pan-BACE antibody will not mislead you. But the moment you leave that controlled setting, discrimination matters.

Why single-clone antibodies commonly cross-react

The catalytic domain of BACE1 and BACE2 is highly conserved because the aspartate motifs (DTG…DSG in both) and the surrounding secondary structure must remain catalytically competent. Any antibody raised against the catalytic domain is at high risk of cross-detection unless the immunizing peptide was specifically selected from a divergent surface loop. Mass-market monoclonal antibodies are often raised against recombinant catalytic domain protein without such peptide selection, and their cross-reactivity is not always disclosed on the datasheet.

The propeptide (residues 22-45 in BACE1, 21-62 in BACE2) is far less conserved — about 32% identity — and is the safest region to target for paralogue-specific antibodies. The cytoplasmic tail (BACE1 residues 480-501 vs BACE2 residues 496-518) is also divergent, particularly around the DISLL/DSTS trafficking motifs, and is a strong secondary region for specificity.

Triple Point's approach — domain-specific polyclonals per paralogue

The Triple Point catalogue provides three domain-specific rabbit polyclonal antibodies per paralogue, raised against non-overlapping peptides selected from regions of low BACE1/BACE2 sequence identity:

Each polyclonal is affinity-purified against its own immunizing peptide, and cross-reactivity against the paralogue's homologous peptide is measured and reported on the Certificate of Analysis. The BACE1 antibodies show <5% cross-reactivity against the equivalent BACE2 region, and vice versa. Where cross-reactivity is measurable, it is documented rather than hidden.

Choosing the right domain antibody for your question

"Is BACE1 protein up- or down-regulated in my sample?"

Use RP2BACE1 (catalytic domain) as the primary detection reagent. Catalytic-domain signal covers both the proenzyme (~70 kDa) and mature enzyme (~50-55 kDa depending on glycosylation state) and gives you the highest sensitivity for total-BACE1 quantitation. For a definitive answer, run RP1BACE1 (propeptide) in parallel — if catalytic signal changes but propeptide signal does not, the change is at the activation step rather than at total protein.

"Is BACE1 being activated in my sample?"

Use RP1BACE1 (propeptide) and RP2BACE1 (catalytic) on the same blot. The propeptide antibody detects only the proenzyme (~70 kDa). The catalytic-domain antibody detects both proenzyme and mature. A decrease in propeptide signal with a corresponding increase in mature-MW catalytic signal is unambiguous evidence of BACE1 activation — typically by furin or a furin-like proprotein convertase in the trans-Golgi.

"Is BACE1 being shed from the membrane?"

Use RP3BACE1 (cytoplasmic tail) and RP2BACE1 (catalytic) on the same blot. Cell lysate should show both. Conditioned media should show catalytic-domain signal at a slightly lower MW (soluble BACE1, sBACE1, ~65 kDa) with no cytoplasmic tail signal — the tail is retained in the membrane fragment after ADAM10-mediated shedding.

"Am I detecting BACE2 in my BACE1 experiment (or vice versa)?"

Run RP2BACE1 and RP2BACE2 on adjacent lanes of the same lysate. If both give strong signal at similar MW, the sample expresses both paralogues (common in pancreatic β-cells, melanocytes, and some cell lines) and you must interpret them separately. If only one paralogue's antibody gives signal, you have confirmed paralogue-specific detection.

Recombinant control proteins

For paralogue-specific validation blots, spike-in controls are the cleanest confirmation. Recombinant human BACE1 (REC-BACE1) and recombinant human BACE2 (REC-BACE2) are supplied as purified extracellular-domain protein. Loaded side-by-side at equimolar amounts, they should show signal only with the matched paralogue antibody. Any signal with the mismatched antibody quantifies the residual cross-reactivity for your specific detection conditions.

Common failure modes and how to catch them

Cross-detection presented as "increased BACE"

A pan-BACE antibody that detects both paralogues will show apparent increases in mixed-expression samples when only one paralogue actually changes. Rerun with paralogue-specific antibodies to resolve which paralogue is responding.

Wrong band size assigned to BACE2

BACE2 is often heavily N-glycosylated (four N-glycosylation sites vs four in BACE1) and runs at 55-65 kDa in mature form. A datasheet expecting BACE1 at ~50 kDa will misassign BACE2 bands as "non-specific" when they are on-target. Check the paralogue-specific expected MW on the Certificate of Analysis.

Loss of BACE2 signal on stripping

BACE2 epitopes appear to be somewhat more sensitive to harsh stripping buffers than BACE1 epitopes. If you are reprobing, run BACE2 detection first, or use a mild stripping buffer — see the stripping buffer recipe.

Cross-species considerations

Human and mouse BACE1 are 96% identical; human and mouse BACE2 are 94% identical. All Triple Point BACE antibodies detect both species and are validated against human, mouse, and rat lysate on the CoA. Cross-reactivity across BACE1 orthologues is expected and correct — cross-reactivity across BACE1/BACE2 paralogues is the problem to control for.

Practical workflow — a suggested paralogue-discrimination blot

1. Run duplicate lanes of your sample lysate (25 μg total protein each) alongside recombinant BACE1 and BACE2 control lanes (10 ng each).
2. Probe one blot with RP2BACE1 (catalytic domain, 1:1,000) overnight at 4°C.
3. Probe the second blot with RP2BACE2 (catalytic domain, 1:1,000) overnight at 4°C.
4. Compare band patterns. The paralogue expressed in your sample will match the matched-paralogue blot; cross-detection at the equivalent MW on the opposite blot quantifies residual cross-reactivity.
5. If both paralogues are present, use the domain-specific antibodies (propeptide vs catalytic vs cytoplasmic tail) to answer the biological question of interest for each paralogue independently.

Ten additional minutes of paralogue control at the start of a project saves months of ambiguous data downstream. This is particularly true for BACE1/BACE2, where the literature contains published claims about "BACE" biology that later turned out to describe the wrong paralogue.

Related

• Anti-BACE1 rabbit polyclonal antibody
• Anti-BACE2 rabbit polyclonal antibody
• Recombinant BACE1 protein
• Recombinant BACE2 protein
• Aspartic proteinase catalog
• Western blot protocol for aspartic proteinases
• Detecting antibody cross-reactivity
• The Superpooled (SPA) method